• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

甲胎蛋白阴性肝细胞癌患者生存预测及预后因素分析:一项基于人群的研究。

Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study.

机构信息

Graduate School of Hebei Medical University, Shijiazhuang, Hebei, China.

Hepatobiliary Surgery Department of the Fourth Hospital of Hebei Medical University, 169 Tianshan Street, Shijiazhuang, Hebei, China.

出版信息

BMC Gastroenterol. 2024 Mar 4;24(1):93. doi: 10.1186/s12876-024-03185-z.

DOI:10.1186/s12876-024-03185-z
PMID:38438972
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10910698/
Abstract

PURPOSE

Hepatocellular carcinoma (HCC) has a poor prognosis, and alpha-fetoprotein (AFP) is widely used to evaluate HCC. However, the proportion of AFP-negative individuals cannot be disregarded. This study aimed to establish a nomogram of risk factors affecting the prognosis of patients with AFP-negative HCC and to evaluate its diagnostic efficiency.

PATIENTS AND METHODS

Data from patients with AFP-negative initial diagnosis of HCC (ANHC) between 2004 and 2015 were collected from the Surveillance, Epidemiology, and End Results database for model establishment and validation. We randomly divided overall cohort into the training or validation cohort (7:3). Univariate and multivariate Cox regression analysis were used to identify the risk factors. We constructed nomograms with overall survival (OS) and cancer-specific survival (CSS) as clinical endpoint events and constructed survival analysis by using Kaplan-Meier curve. Also, we conducted internal validation with Receiver Operating Characteristic (ROC) analysis and Decision curve analysis (DCA) to validate the clinical value of the model.

RESULTS

This study included 1811 patients (1409 men; 64.7% were Caucasian; the average age was 64 years; 60.7% were married). In the multivariate analysis, the independent risk factors affecting prognosis were age, ethnicity, year of diagnosis, tumor size, tumor grade, surgery, chemotherapy, and radiotherapy. The nomogram-based model related C-indexes were 0.762 (95% confidence interval (CI): 0.752-0.772) and 0.752 (95% CI: 0.740-0.769) for predicting OS, and 0.785 (95% CI: 0.774-0.795) and 0.779 (95% CI: 0.762-0.795) for predicting CSS. The nomogram model showed that the predicted death was consistent with the actual value. The ROC analysis and DCA showed that the nomogram had good clinical value compared with TNM staging.

CONCLUSION

The age(HR:1.012, 95% CI: 1.006-1.018, P-value < 0.001), ethnicity(African-American: HR:0.946, 95% CI: 0.783-1.212, P-value: 0.66; Others: HR:0.737, 95% CI: 0.613-0.887, P-value: 0.001), tumor diameter(HR:1.006, 95% CI: 1.004-1.008, P-value < 0.001), year of diagnosis (HR:0.852, 95% CI: 0.729-0.997, P-value: 0.046), tumor grade(Grade 2: HR:1.124, 95% CI: 0.953-1.326, P-value: 0.164; Grade 3: HR:1.984, 95% CI: 1.574-2.501, P-value < 0.001; Grade 4: HR:2.119, 95% CI: 1.115-4.027, P-value: 0.022), surgery(Liver Resection: HR:0.193, 95% CI: 0.160-0.234, P-value < 0.001; Liver Transplant: HR:0.102, 95% CI: 0.072-0.145, P-value < 0.001), chemotherapy(HR:0.561, 95% CI: 0.471-0.668, P-value < 0.001), and radiotherapy(HR:0.641, 95% CI: 0.463-0.887, P-value:0.007) were independent prognostic factors for patients with ANHC. We developed a nomogram model for predicting the OS and CSS of patients with ANHC, with a good predictive performance.

摘要

目的

肝细胞癌(HCC)预后较差,甲胎蛋白(AFP)广泛用于评估 HCC。然而,不能忽视 AFP 阴性个体的比例。本研究旨在建立 AFP 阴性 HCC 患者预后影响因素的列线图,并评估其诊断效率。

方法

从 2004 年至 2015 年期间 Surveillance, Epidemiology, and End Results 数据库中收集 AFP 阴性初诊 HCC(ANHC)患者的数据,用于模型建立和验证。我们将整体队列随机分为训练或验证队列(7:3)。采用单因素和多因素 Cox 回归分析确定风险因素。我们以总生存(OS)和癌症特异性生存(CSS)为临床终点事件构建列线图,并通过 Kaplan-Meier 曲线进行生存分析。我们还通过接受者操作特征(ROC)分析和决策曲线分析(DCA)进行内部验证,以验证模型的临床价值。

结果

本研究纳入了 1811 例患者(1409 例男性;64.7%为白种人;平均年龄为 64 岁;60.7%已婚)。多因素分析显示,影响预后的独立危险因素为年龄、种族、诊断年份、肿瘤大小、肿瘤分级、手术、化疗和放疗。基于列线图的模型相关 C 指数分别为 0.762(95%置信区间(CI):0.752-0.772)和 0.752(95% CI:0.740-0.769),用于预测 OS,0.785(95% CI:0.774-0.795)和 0.779(95% CI:0.762-0.795)用于预测 CSS。列线图模型表明,预测死亡率与实际死亡率一致。ROC 分析和 DCA 表明,与 TNM 分期相比,列线图具有较好的临床价值。

结论

年龄(HR:1.012,95%CI:1.006-1.018,P 值<0.001)、种族(非裔美国人:HR:0.946,95%CI:0.783-1.212,P 值:0.66;其他:HR:0.737,95%CI:0.613-0.887,P 值:0.001)、肿瘤直径(HR:1.006,95%CI:1.004-1.008,P 值<0.001)、诊断年份(HR:0.852,95%CI:0.729-0.997,P 值:0.046)、肿瘤分级(Grade 2:HR:1.124,95%CI:0.953-1.326,P 值:0.164;Grade 3:HR:1.984,95%CI:1.574-2.501,P 值<0.001;Grade 4:HR:2.119,95%CI:1.115-4.027,P 值:0.022)、手术(肝切除术:HR:0.193,95%CI:0.160-0.234,P 值<0.001;肝移植术:HR:0.102,95%CI:0.072-0.145,P 值<0.001)、化疗(HR:0.561,95%CI:0.471-0.668,P 值<0.001)和放疗(HR:0.641,95%CI:0.463-0.887,P 值:0.007)是影响 ANHC 患者预后的独立预测因素。我们开发了一种预测 ANHC 患者 OS 和 CSS 的列线图模型,具有良好的预测性能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79bc/10910698/33d91bac63fa/12876_2024_3185_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79bc/10910698/b5904944bfb3/12876_2024_3185_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79bc/10910698/33d91bac63fa/12876_2024_3185_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79bc/10910698/b5904944bfb3/12876_2024_3185_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/79bc/10910698/33d91bac63fa/12876_2024_3185_Fig2_HTML.jpg

相似文献

1
Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study.甲胎蛋白阴性肝细胞癌患者生存预测及预后因素分析:一项基于人群的研究。
BMC Gastroenterol. 2024 Mar 4;24(1):93. doi: 10.1186/s12876-024-03185-z.
2
Construction of webbased prediction nomogram models for cancerspecific survival in patients at stage IV of hepatocellular carcinoma depending on SEER database.基于监测、流行病学和最终结果(SEER)数据库构建用于预测肝细胞癌IV期患者癌症特异性生存的网络预测列线图模型。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023 Oct 28;48(10):1546-1560. doi: 10.11817/j.issn.1672-7347.2023.230040.
3
Development and evaluation of nomograms and risk stratification systems to predict the overall survival and cancer-specific survival of patients with hepatocellular carcinoma.开发和评估列线图和风险分层系统,以预测肝细胞癌患者的总生存率和癌症特异性生存率。
Clin Exp Med. 2024 Feb 28;24(1):44. doi: 10.1007/s10238-024-01296-1.
4
Construction and validation of a survival prognostic model for stage III hepatocellular carcinoma: a real-world, multicenter clinical study.构建并验证 III 期肝细胞癌生存预后模型:一项真实世界、多中心临床研究。
BMC Gastroenterol. 2023 Jun 13;23(1):207. doi: 10.1186/s12876-023-02820-5.
5
A prognostic nomogram based on LASSO Cox regression in patients with alpha-fetoprotein-negative hepatocellular carcinoma following non-surgical therapy.基于 LASSO Cox 回归的 AFP 阴性肝癌患者非手术治疗后预后列线图。
BMC Cancer. 2021 Mar 8;21(1):246. doi: 10.1186/s12885-021-07916-3.
6
OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma.OHCCPredictor:一个用于预测老年肝细胞癌患者生存时间的在线风险分层模型。
Hepatol Int. 2024 Apr;18(2):550-567. doi: 10.1007/s12072-023-10516-x. Epub 2023 Apr 17.
7
Preoperative contrast-enhanced computed tomography-based radiomics model for overall survival prediction in hepatocellular carcinoma.基于术前增强 CT 的影像组学模型预测肝细胞癌患者总生存期。
World J Gastroenterol. 2022 Aug 21;28(31):4376-4389. doi: 10.3748/wjg.v28.i31.4376.
8
Construction and validation of a nomogram for patients with multiple hepatocellular carcinoma: A SEER-based study.构建并验证基于 SEER 数据库的多中心肝细胞癌患者列线图模型。
Eur J Surg Oncol. 2023 Oct;49(10):106966. doi: 10.1016/j.ejso.2023.06.018. Epub 2023 Jun 21.
9
Construction and validation of a nomogram for predicting cancer-specific survival in middle-aged patients with advanced hepatocellular carcinoma: A SEER-based study.构建并验证基于 SEER 数据库的用于预测中年晚期肝细胞癌患者癌症特异性生存的列线图
Medicine (Baltimore). 2024 Sep 20;103(38):e39480. doi: 10.1097/MD.0000000000039480.
10
Development and validation of a nomogram to predict cancer-specific survival of patients with large hepatocellular carcinoma accepting surgical resection: a real-world analysis based on the SEER database.预测接受手术切除的大肝细胞癌患者癌症特异性生存的列线图的开发与验证:基于监测、流行病学和最终结果(SEER)数据库的真实世界分析
J Gastrointest Oncol. 2024 Aug 31;15(4):1657-1673. doi: 10.21037/jgo-24-285. Epub 2024 Aug 20.

引用本文的文献

1
Circulatory Agrin Serves as a Prognostic Indicator for Hepatocellular Carcinoma.循环聚集蛋白聚糖作为肝细胞癌的预后指标。
Cancers (Basel). 2024 Jul 31;16(15):2719. doi: 10.3390/cancers16152719.

本文引用的文献

1
Comparative Analysis of Subclassification Systems in Patients with Intermediate-Stage Hepatocellular Carcinoma (Barcelona Clinic Liver Classification B) Receiving Systemic Therapy.接受全身治疗的中期肝细胞癌患者(巴塞罗那临床肝癌分期B期)分类系统的比较分析
Curr Oncol. 2024 Jan 19;31(1):547-557. doi: 10.3390/curroncol31010038.
2
Transcatheter arterial chemoembolisation combined with lenvatinib plus camrelizumab as conversion therapy for unresectable hepatocellular carcinoma: a single-arm, multicentre, prospective study.经动脉化疗栓塞联合乐伐替尼加卡瑞利珠单抗作为不可切除肝细胞癌的转化治疗:一项单臂、多中心、前瞻性研究
EClinicalMedicine. 2023 Dec 12;67:102367. doi: 10.1016/j.eclinm.2023.102367. eCollection 2024 Jan.
3
Clinical efficacy and safety evaluation of camrelizumab plus lenvatinib in adjuvant therapy after hepatocellular carcinoma surgery.
卡瑞利珠单抗联合仑伐替尼用于肝细胞癌术后辅助治疗的临床疗效及安全性评估
Front Oncol. 2023 Dec 13;13:1174999. doi: 10.3389/fonc.2023.1174999. eCollection 2023.
4
Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence.新辅助卡博替尼和纳武利尤单抗治疗晚期肝细胞癌的空间转录组学分析,确定了耐药和复发的独立机制。
Genome Med. 2023 Sep 18;15(1):72. doi: 10.1186/s13073-023-01218-y.
5
Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma.转移部位对接受一线索拉非尼治疗的晚期肝细胞癌患者的预后影响
Cancers (Basel). 2023 Feb 28;15(5):1523. doi: 10.3390/cancers15051523.
6
TKIs in combination with immunotherapy for hepatocellular carcinoma.酪氨酸激酶抑制剂联合免疫疗法治疗肝细胞癌。
Expert Rev Anticancer Ther. 2023 Mar;23(3):279-291. doi: 10.1080/14737140.2023.2181162. Epub 2023 Feb 26.
7
Social determinants of health impact mortality from HCC and cholangiocarcinoma: a population-based cohort study.社会决定因素对 HCC 和胆管癌死亡率的影响:基于人群的队列研究。
Hepatol Commun. 2023 Feb 9;7(3):e0058. doi: 10.1097/HC9.0000000000000058. eCollection 2023 Mar 1.
8
Impact of marital status on overall survival in patients with early-stage hepatocellular carcinoma.婚姻状况对早期肝细胞癌患者总生存的影响。
Sci Rep. 2022 Nov 19;12(1):19923. doi: 10.1038/s41598-022-14120-1.
9
The Performance of Serum Alpha-Fetoprotein for Detecting Early-Stage Hepatocellular Carcinoma Is Influenced by Antiviral Therapy and Serum Aspartate Aminotransferase: A Study in a Large Cohort of Hepatitis B Virus-Infected Patients.血清甲胎蛋白检测早期肝细胞癌的性能受抗病毒治疗和血清天门冬氨酸氨基转移酶的影响:一项在乙型肝炎病毒感染患者大队列中的研究。
Viruses. 2022 Jul 29;14(8):1669. doi: 10.3390/v14081669.
10
Risk factors and predictive nomograms for early death of patients with advanced hepatocellular carcinoma: a large retrospective study based on the SEER database.基于 SEER 数据库的大样本回顾性研究:晚期肝细胞癌患者早期死亡的风险因素和预测列线图。
BMC Gastroenterol. 2022 Jul 19;22(1):348. doi: 10.1186/s12876-022-02424-5.